Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years' follow-up in first-line advanced renal cell carcinoma

Press/Media

Period	13 Feb 2023

Media coverage

Title	Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years' follow-up in first-line advanced renal cell carcinoma
Media name/outlet	Hugin - English
Country/Territory	United States
Date	13/02/23
URL	ct.moreover.com/?a=50003748360&p=1gw&v=1&x=VeMyN2piR0zNAxeIdrrZlg
Persons	Mauricio Burotto